Karin Przyklenk

Karin Przyklenk

Professor w/tenure
Director, Cardiovascular Research Institute (CVRI)

kprzykle@med.wayne.edu

Karin Przyklenk

Office Phone

313-577-9047

Office Location

540 East Canfield
Detroit, MI 48201

Education

Ph.D
Department of Biophysics
University of Western Ontario
London, Ontario, Canada

B.Sc. (Honors)
Physics and Biology
University of Saskatchewan
Saskatoon, Saskatchewan, Canada

Education – Degrees, Licenses, Certifications

Ph.D.

Fellowships

Post Doctoral Research Fellow
Department of Internal Medicine, Division of Cardiology
Wayne State University/Harper Hospital
Detroit, MI
1985

Post-Doctoral Research Fellow
Department of Medicine
Harvard Medical School
Boston, MA
1983-1984

Prior Appointments

Director, Cardiovascular Research Institute
Wayne State University School of Medicine
Detroit, MI
2/2008 - Present

Professor (with Tenure)
Departments of Physiology and Emergency Medicine
Associate Member, Center for Molecular Medicine & Genetics (05/2008)
Wayne State University School of Medicine
Detroit, MI
2/2008 - Present

Professor
Emergency Medicine, Anesthesiology and Medicine (Cardiology)
Faculty Member, Center for Platelet Function Studies
University of Massachusetts Medical School
Worcester, MA
2002 - 1/2008

Assistant Director of Research and Director of Cardiac Function
Heart Institute, Hospital of the Good Samaritan
Los Angeles, CA
1988 - 2002

Associate Professor of Research Medicine
Department of Medicine, Section of Cardiology
University of Southern California
Los Angeles, CA
1992 - 2002

Assistant Professor of Research Medicine
Department of Medicine, Section of Cardiology
University of Southern California
Los Angeles, CA
1988 - 1992

Assistant Professor
Department of Internal Medicine, Division of Cardiology
Wayne State University/Harper Hospital
Detroit, MI
1986 - 1988
 

Accomplishments

“Outstanding Faculty Mentor Award”
Wayne State University School of Medicine
2014

Visiting Scientist
UMASS – Sapporo Medical University Academic Exchange Program
Hosted by 2nd Department of Internal Medicine (Drs. Miura & Shimamoto)
Sapporo Medical University
June 2004

20th Anniversary: ‘Best of’ Cardiovascular Reviews and Reports for the manuscript "Recent advances in stunned myocardium", originally published October 1987 and updated June 1990
July 2000

"People Who Make a Difference"
Research Highlights of the American Heart Association (Greater Los Angeles Affiliate)
1992

Master Teacher Award from
Cardiovascular Reviews and Reports for the manuscript "Recent advances in stunned myocardium", originally published October 1987 and updated June 1990
June 1990

Medical Research Council of Canada
Post-Doctoral Fellowship Award
1983-1985

Medical Research Council of Canada
Graduate Studentship Award
1978 - 1982
 

Professional Experience

SCIENTIFIC COMMITTEES, STUDY SECTIONS AND OTHER ACADEMIC ACTIVITIES


Member
European Research Council (ERC) Starting Grants Evaluation Committee
2018 - Present

Member
American Physiological Society (APS)/American Journal of Physiology (AJP) Writing Group: ‘Animal Models of Myocardial Ischemia and Infarction’
2017 - Present

Member
Protocol Review and Monitoring Committee (PRMC), NIH/NHLBI Preclinical Consortium to Facilitate Translation and Cardioprotective Therapies (CAESAR)
2010 - Present

Member
NIH/NHLBI Myocardial Ischemia and Metabolism (MIM) Study Section
2010 - 2016

External Grant Reviewer
Diabetes UK
2015

Member
NIH/NHLBI Special Emphasis Panel: PPG Review
2014

External grant reviewer
British Heart Foundation
2014

Chair
Scientific session “Protection of Ischemic Myocardium IV” at the 2012 Scientific Sessions of the American Heart Association
Los Angeles CA.
2012

Chair
Scientific session “Cardioprotection in the Presence of Cardiovascular Risk Factors” at the 75th Anniversary of Albert Szent-Györgyi’s Nobel Prize Award, March 22nd-25th 2012,
Szeged Hungary
2012

Chair
Oral session “Novel strategies in myocardial protection” at the 9th International Congress on Coronary Artery Disease
Venice Italy
2011

External grant reviewer
HRB (Health Research Board – Ireland)
2011 - 2012

External grant reviewer
HRUK (Heart Research – United Kingdom)
2011

External grant reviewer
Ontario Research Fund
2010 - 2011

Member
NIH/NHLBI Workshop: New Horizons in Cardioprotection
September 20th-21st 2010 
Bethesda MD
2010

Moderator
Poster session “Risk factors for cardiac events” at the XX World Congress, International Society for Heart Research
Kyoto Japan
2010

Invited Judge
Inaugural Graduate School Exhibition
Wayne State University, Detroit MI.
2010

External grant reviewer
Alberta Heritage Foundation for Medical Research
2009 - 2010

Chair
Scientific session “Experimental Myocardial Infarction: Cell Therapy, Remodeling, Cardioprotection” at the 2009 Scientific Sessions of the American Heart Association
Orlando FL
2009

Ad hoc member
NIH/NHLBI Myocardial Ischemia and Metabolism (MIM) Study Section
2009

Organizing Committee and Session Chair
Cardioprotection and its Clinical Application: 14th International Symposium
November 8th 2008
New Orleans, LA
2008

Chair
Plenary Session "Modulation of Ischemia-Reperfusion Injury: Novel Biomarkers” at the 14th World Congress on Heart Disease,
July 28th-31st 2008
Toronto, Canada.
2008

Invited Judge,
Annual Research Symposium of Henry Ford Health System
Detroit MI
2008

Member
NIH/NHLBI Special Emphasis Panel: ZRG1 CVS-K(02)
2008

Chair
Scientific session "New Advances in Cardioprotection” at the 56th Annual Scientific Sessions of the American College of Cardiology
New Orleans LA
2007

Distinguished Correspondent
Sociedad Iberoamericana de Información Científica (SIIC) Program of Scientific Bureaus
2007

Ad hoc external consultant
Senior Appointments and Promotions Committee, University of Connecticut School of Medicine
2007

Abstract Grader
World Congress of Cardiology/European Society of Cardiology Congress
2006, 2009, 2010

Member, Grants Committee, Society for Academic Emergency Medicine
2005 - 2007

External Grant Reviewer
Biomedical Research Council of Singapore
2005 - 2007

Member
NIH/NHLBI Review Panel: Program Project P01 HL080103
2004 - 2005

External Grant Reviewer
Wellcome Trust
London UK
2004

Member
NIH/NHLBI Special Emphasis Panel: ZRG1 CVS-F(04)
2004

Abstract Grader
Annual Scientific Sessions of the Society for Academic Emergency Medicine
2004 - 2008

Scientific Executive Committees
International Academy of Cardiology and Annual Meeting of the World Congress on Heart Disease
2003 - Present

Abstract Grader
Annual Scientific Sessions of the American College of Cardiology
2003 - 2009

Abstract Grader
Annual Scientific Sessions of the American Heart Association
1993 - 2009 & 2003 - 2010

Member
Cardiovascular (Patho)Physiology II Study Section
American Heart Association (National)
2003

Ad hoc member
CVA Study Section, NIH/NHLBI (March 2002)
2002

Chair
Scientific session “Signaling Pathways in Preconditioning” at the 73rd Annual Scientific Sessions of the American Heart Association
New Orleans LA
2000

Chair
Scientific session “Apoptosis in Myocardial Ischemia” at the 71st Annual Scientific Sessions of the American Heart Association
Dallas TX
1998

1International Advisory Committee for the conference “Heart in Stress”, June 28 - July 3 1998
Lahti Finland
1997 - 1998

Chair
Scientific session “Mechanisms of Ischemic Preconditioning II” at the 70th Annual Scientific Sessions of the American Heart Association
Orlando FL
1997

External grant reviewer
Jewish Hospital Foundation
Louisville, KY
1997 & 1998

Chair
Scientific session "Mechanisms of Ischemic Preconditioning" at the 69th Annual Scientific Sessions of the American Heart Association
New Orleans, LA
1996

Judge
Laverna Titus Young Investigators Forum
American Heart Association (Greater Los Angeles Affiliate)
1996

External grant reviewer
Heart and Stroke Foundation of Canada
1995

External grant reviewer
Research Institute, William Beaumont Hospital
Royal Oak MI.
1995

Chair
Scientific session "Preconditioning and Stunning" at the 44th Annual Scientific Sessions of the American College of Cardiology
New Orleans LA
1995

Chair
Laverna Titus Young Investigators Forum
American Heart Association (Greater Los Angeles Affiliate)
1995

Chair
Moderated poster session "Stunned myocardium" at the 66th Annual Scientific Sessions of the American Heart Association
Atlanta GA.
1993

Chair
Scientific session "Ischemic Preconditioning" at the 64th Annual Scientific Sessions of the American Heart Association
Anaheim CA
1991

Study Session
National Merit Review, Board for Cardiology, Department of Veterans Affairs
1991

Fellowship/Clinician-Scientist/Investigative Group Study Sections 
American Heart Association (Greater Los Angeles Affiliate)
1988 - 1995

ADMINISTRATIVE COMMITTEES

Member
Executive Committee of the Wayne State University School of Medicine Faculty Council on Philanthropy
2016 - Present
 

Member
Review Advisory Panel for the 7-Year Academic Program Review of the Department of Anatomy and Cell Biology
Wayne State University School of Medicine
2015 - 2016

Member
Translational Research Working Group
Member, Core Facilities Working Group (Laboratory Animal Resources Sub-committee)
Wayne State University School of Medicine Research Strategic Planning
2011 - 2012

Member
Institutional Animal Care and Use Committee,
Wayne State University
(Full Member: 2009-2011; Alternate: 2011-present)
2009 - Present

Member
Promotions and Merit Review Committee
Member, Budget Committee (2014-present)
Department of Emergency Medicine
Wayne State University School of Medicine
2009 - Present

Member
Budget Committee (2008-2015)
Member, Faculty Search Committee (2008-2012) and
Member, Promotion and Tenure Committee (2008-2009)
Department of Physiology,
Wayne State University School of Medicine
2008 - 2015

Member
Research Steering Committee
Department of Internal Medicine
Wayne State University School of Medicine
2009 - Present

Member
Faculty Development Advisory Council
University of Massachusetts Medical School
2007 - 2008

Member
Search Committee for Chair of Quantitative Health Sciences
University of Massachusetts Medical School
2007

Member
Faculty Promotion-Personnel Action Committee
University of Massachusetts Medical School
2006 - 2008

Chair (2005-08) and Member (2003-08)
Departmental Promotion- Personnel Action Committee
Department of Emergency Medicine
University of Massachusetts Medical School
2003 - 2008

Member
Governing Board
California Biomedical Research Association
1997 - 2002

Member
Budget Planning Task Force
American Heart Association (Greater Los Angeles Affiliate)
1997

Member
Finance & Administration Committee
Member, Research Committee
American Heart Association (Greater Los Angeles Affiliate)
1994 - 1998

Vice Chair
Investigative Group Study Session
American Heart Association (Greater Los Angeles Affiliate)
1993 & 1994
 

 

Publications

 PEER-REVIEWED PUBLICATIONS

1. Przyklenk K, Groom AC. Microvascular evidence for a `transition zone' around a chronic myocardial infarct in the rat. Can J Physiol Pharmacol 1983; 61: 1516-1522.

2. Przyklenk K, Groom AC. Can exercise promote revascularization in the transition zone of infarcted rat hearts? Can J Physiol Pharmacol 1984; 62: 630-633.

3. Przyklenk K, Groom AC. Effect of exercise frequency, intensity and duration on revascularization in the transition zone of infarcted rat hearts. Can J Physiol Pharmacol 1985; 63: 273-278.

4. Przyklenk K, Vivaldi MT, Arnold JMO, Schoen FJ, Kloner RA. Capillary anastomoses between the left anterior descending and circumflex circulations in the canine heart: possible importance during coronary artery occlusion. Microvasc Res 1986; 31: 54-65.

5. Przyklenk K, Vivaldi MT, Arnold JMO, Schoen FJ, Kloner RA. Salvage of ischemic myocardium by reperfusion: importance of collateral blood flow and oxygen demand during occlusion. Cardiovasc Res 1986; 20: 403-414.

6. Przyklenk K, Kloner RA. Superoxide dismutase plus catalase improve contractile function in the canine model of the stunned myocardium. Circ Res 1986; 58: 148-156.

7. Arnold JMO, Antman EM, Przyklenk K, Braunwald E, Sandor T, Vivaldi MT, Schoen FJ, Kloner RA Differential effects of reperfusion on incidence of ventricular arrhythmias and recovery of ventricular function at 4 days following coronary occlusion. Am Heart J 1987; 113: 1055-1065.

8. Przyklenk K, Kloner RA. Effect of oxygen-derived free radicals on infarct size following six hours of permanent coronary artery occlusion: salvage or delay of myocyte necrosis? Basic Res Cardiol 1987; 82: 146-158.

9. Przyklenk K, Connelly CM, McLaughlin RJ, Kloner RA, Apstein CS. Effect of myocyte necrosis on strength, strain and stiffness of isolated myocardial strips. Am Heart J 1987; 114: 1349-1359.

10. Przyklenk K, Kloner RA. Acute effects of hydralazine and enalapril on contractile function of postischemic stunned myocardium. Am J Cardiol 1987; 60: 934-936..

11. Przyklenk K, Kloner RA. Diastolic abnormalities of postischemic stunned myocardium. Am J Cardiol 1987; 60: 1211-1213.

12. Przyklenk K, Kloner RA. Effect of verapamil on postischemic stunned myocardium: importance of the timing of treatment. J Am Coll Cardiol 1988; 11: 614-623.

13. Przyklenk K, Kloner RA. "Reperfusion injury" by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature and regional myocardial blood flow. Circ Res 1989; 64: 86-96.

14. Przyklenk K, Ghafari GB, Eitzman DT, Kloner RA. Nifedipine administered after reperfusion ablates systolic contractile dysfunction of postischemic stunned myocardium. J Am Coll Cardiol 1989; 13: 1176-1183.

15. Przyklenk K. Effect of chronic ibuprofen therapy on healing of experimentally-induced acute myocardial infarction in dogs. Am J Cardiol 1989; 63: 1146-1148.

16. Reddy BR, Kloner RA, Przyklenk K. Early treatment with the iron chelator deferoxamine limits infarct size in a canine model of coronary occlusion and reperfusion. Free Radical Biol Med 1989; 7: 45-52.

17. Przyklenk K, Kloner RA. Is stunned myocardium a protective mechanism? Effect of acute alterations in myocardial oxygen demand on recovery of contractile function and high energy phosphate stores at 1 day post-reperfusion. Am Heart J 1989; 118: 480-489.

18. Kloner RA, Przyklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischemia/reperfusion: resolved and unresolved issues. Circulation 1989; 80: 1115-1127.

19. Przyklenk K, Whittaker P, Kloner RA. In vivo infusion of free radical substrates causes myocardial systolic, but not diastolic, dysfunction. Am Heart J 1990; 119: 807-815.

20. Whittaker P, Boughner DR, Kloner RA, Przyklenk K. Stunned myocardium and collagen damage: differential effects of single and repeated occlusions. Am Heart J 1991; 121: 434-441.

21. Przyklenk K, Kloner RA. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am Heart J 1991; 121: 1319-1330.

22. Reddy BR, Wynne J, Kloner RA, Przyklenk K. Pretreatment with the iron chelator deferoxamine fails to provide sustained protection against myocardial ischemia/reperfusion injury. Cardiovasc Res 1991; 25: 711-718.

23. Przyklenk K, Bauer B, Kloner RA. Reperfusion of "hibernating" myocardium: contractile function, high energy phosphate content and myocyte injury following 3 hours of sublethal ischemia and 3 hours of reperfusion in the canine model. Am Heart J 1992; 123: 575-588.

24. Ovize M, Kloner RA, Hale SL, Przyklenk K. Coronary cyclic flow variations "precondition" the ischemic myocardium. Circulation 1992; 85: 779-787.

25. Ovize M, Przyklenk K, Hale SL, Kloner RA. Preconditioning does not attenuate myocardial stunning. Circulation 1992; 85: 2247-2254.

26. Ovize M, Przyklenk K, Kloner RA. Partial stenosis is sufficient, and complete reperfusion is mandatory, to induce preconditioning. Circ Res 1992; 71: 1165-1173.

27. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic "preconditioning" protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993; 87: 893-899.

28. Simkhovich BZ, Hale SL, Ovize M, Przyklenk K, Kloner RA. Ischemic preconditioning and long chain acyl carnitine in the canine heart. Coronary Artery Dis 1993; 4: 387-392.

29. Przyklenk K, Kloner RA. Oxygen radical scavenging agents as "adjuvant therapy" with tissue plasminogen activator in a canine model of coronary thrombolysis. Cardiovasc Res 1993; 27: 925-934.

30. Whittaker P, Kloner RA, Przyklenk K. Laser-mediated transmural myocardial channels do not salvage ischemic myocardium. J Am Coll Cardiol 1993; 22: 302-309.

31. Bauer B, Simkhovich B, Kloner RA, Przyklenk K. Does preconditioning protect the coronary vasculature from subsequent ischemia/reperfusion injury? Circulation 1993; 88: 659-672.

32. Ovize M, Kloner RA, Przyklenk K. Stretch preconditions the canine myocardium. Am J Physiol 1994; 266: H137-H146.

33. Whittaker P, Przyklenk K. Reduction of infarct size with ischemic preconditioning: mathematical evidence for protection via non-ischemic tissue. Basic Res Cardiol 1994; 89: 6-15.

34. Przyklenk K. Nicotine exacerbates postischemic contractile dysfunction of stunned myocardium in the canine model: possible role of free radicals. Circulation 1994; 89: 1272-1281.

35. Przyklenk K, Aoki A, Bellows S, Kleindienst D, Zubiate P Jr, Hale SL, Simkhovich BZ, Kloner RA, Kay GL. Stunned myocardium following prolonged cardiopulmonary bypass: Effect of warm vs. cold cardioplegia in the canine model. J Cardiac Surg 1994; 9: 506-516.

36. Przyklenk K, Simkhovich BZ, Bauer B, Kloner RA. Deterioration in myocardial blood flow following relief of sustained ischemia is not associated with release of endothelin into the coronary sinus. Basic Res Cardiol 1994; 89: 260-269.

37. Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S, Gibson M, Poole K, Cannon CP, McCabe C, Braunwald E, and the TIMI-4 Investigators. Previous angina alters in-hospital outcome in TIMI-4: A Clinical correlate to preconditioning? Circulation 1995; 91: 37-47.

38. Przyklenk K, Ovize M, Bauer B, Kloner RA. Gender does not influence the pathophysiology of acute myocardial infarction in dogs. Am Heart J 1995; 129: 1108-1113.

39. Przyklenk K, Kloner RA. Low dose IV acetylcholine acts as a "preconditioning-mimetic" in the canine model. J Cardiac Surg 1995; 10: 389-395.

40. Przyklenk K, Sussman MA, Simkhovich BZ, Kloner RA. Does ischemic preconditioning trigger translocation of protein kinase C in the canine model? Circulation 1995; 92: 1546-1557.

41. Simkhovich BZ, Whittaker P, Przyklenk K, Kloner RA. Transient pre-ischemic acidosis protects the isolated rabbit heart subjected to 30 minutes, but not 60 minutes, of global ischemia. Basic Res Cardiol 1995; 90: 397-403.

42. Whittaker P, Kloner RA, Przyklenk K. Intramyocardial injections and protection against myocardial ischemia: An attempt to explain the cardioprotective actions of adenosine. Circulation 1996; 93:2043-2051.

43. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Reduction of infarct size with ischemic preconditioning and MLA: role of adenosine regulating enzymes? Am J Physiol 1996; 271: H1004-H1014.

44. Simkhovich BZ, Przyklenk K, Hale SL, Patterson M, Kloner RA. Direct evidence that preconditioning does not cause protein kinase C translocation in rabbit heart. Cardiovasc Res 1996; 32: 1064-1070.

45. Przyklenk K, Hata K, Zhao L, Kloner RA, Elliott GT. Disparate effects of preconditioning and MLA on 5' nucleotidase and adenosine levels during coronary occlusion. Am J Physiol 1997; 273: H945-H951.

46. Przyklenk K, Hata K, Kloner RA. Is calcium a mediator of infarct size reduction with preconditioning in canine myocardium? Circulation 1997; 96: 1305-1312.

47. Hata K, Whittaker P, Kloner RA, Przyklenk K. Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries: role of adenosine. Circulation 1998; 97: 692-702.

48. Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K, McCabe CH, Braunwald E, and TIMI 9B Investigators. Prospective temporal analysis of the onset of preinfarct angina versus outcome: an ancillary study in TIMI 9-B. Circulation 1998;97: 1042-1045

49. Simkhovich BZ, Kloner RA, Przyklenk K. Time course of protein kinase C translocation in globally ischemic rabbit heart. Basic Res Cardiol 1998; 93: 122-126.

50. Kloner RA, Przyklenk K, Shook T, Cannon C. Protection conferred by preinfarct angina is manifest in the aged heart: evidence from the TIMI-4 trial. J Thromb Thrombolysis 1998; 6: 89-92.

51. Bauer B, Simkhovich BZ, Kloner R.A, Przyklenk K. Preconditioning-induced cardioprotection and release of the second messenger inositol (1,4,5)-trisphosphate are both blocked by neomycin in rabbit heart. Basic Res Cardiol 1999; 94: 31-40.

52. Hata K, Kloner RA, Whittaker P, Przyklenk K. Brief myocardial ischemia attenuates platelet aggregation in remote, damaged and stenotic carotid arteries via an adenosine-mediated mechanism. Circulation 1999; 100: 843-848.

53. Dickson EW, Lorbar M, Porcaro WA, Fenton R, Reinhardt C, Gysembergh A, Przyklenk, K. Rabbit heart can be ‘preconditioned’ via transfer of coronary effluent. Am J Physiol 1999; 277: H2451-H2457.

54. Gysembergh A, Lemaire S, Sportouch C, Piot C, Richard S, Kloner RA, Przyklenk K. Pharmacologic manipulation of inositol (1,4,5)-trisphosphate signaling mimics preconditioning in rabbit heart. Am J Physiol 1999; 277: H2458-H2469.

55. Przyklenk K, Hata K, Whittaker P, Elliott GT. Monophosphoryl lipid A: a novel nitric oxide-mediated therapy to attenuate platelet aggregation? J. Cardiovasc Pharmacol 2000; 35: 366-375.

56. Dickson EW, Porcaro WA, Fenton R, Heard SO, Reinhardt C, Renzi FP, Przyklenk K. “Preconditioning at a distance” in the isolated rabbit heart. Acad Emergency Med 2000; 7: 311-317.

57. Przyklenk K, Whittaker P. Brief antecedent ischemia enhanced recombinant tissue plasminogen activator-induced coronary thrombolysis by adenosine-mediated mechanism. Circulation 2000; 102: 88-95.

58. Przyklenk K, Kloner RA. Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery thrombosis. J Am Coll Cardiol 2001; 37: 286-292.

59. Gysembergh A, Kloner RA, Przyklenk K. p38 MAPK activity is not increased early during sustained coronary occlusion in preconditioned versus control rabbit heart. J Mol Cell Cardiol 2001; 33: 681-690.

60. Gysembergh A, Kloner RA, Przyklenk K. The gap junction uncoupler heptanol does not limit ischemia-induced necrosis in rabbit heart. Cardiovasc Pathol 2001; 10: 13-17.

61. Horn M, Weidensteiner C, Scheffer H, Meininger M, de Groot M, Remkes H, Dienesch C, Przyklenk K, von Klein M, Neubauer S. Detection of myocardial viability based on measurements of sodium content: a 23Na-NMR study. Magn Reson Med 2001; 45: 756-764.

62. Dickson EW, Blehar DJ, Carraway RE, Heard SO, Steinberg G, Przyklenk K. Naloxone blocks transferred preconditioning in isolated rabbit hearts. J Mol Cell Cardiol 2001; 33: 1751-1756.

63. Przyklenk K, Li G, Whittaker P. No loss in the in vivo efficacy of ischemic preconditioning in middle-aged and old rabbits. J Am Coll Cardiol 2001; 38: 1741-1747.

64. Kloner RA, Poole K, Shook T, Przyklenk K, Peritt K, Cannon C. Comparison of acute myocardial infarct size in patients > 65 years versus < 65 years in the prethrombolytic period versus the thrombolytic period. Am J Cardiol 2002; 89: 1291-1293.

65. Tubbs RJ, Porcaro WA, Lee W J, Blehar DJ, Carraway RE, Przyklenk K, Dickson EW. Delta opiates increase ischemic tolerance in isolated rabbit jejunum. Acad Emerg Med. 2002; 9: 555-560.

66. Li G, Whittaker P, Yao M, Kloner RA, Przyklenk K. The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse heart. Cardiovasc Pathol 2002; 11: 158-165.

67. Dickson EW, Tubbs RJ, Porcaro WA, Lee W J, Blehar DJ, Carraway RE, Darling C, Przyklenk K. Myocardial preconditioning factors evoke mesenteric ischemic tolerance via opioid receptors and KATP channels. Am J Physiol 2002; 283: H22-H28.

68. Przyklenk K, Li G, Simkhovich BZ, Kloner RA. Mechanisms of preconditioning are age-related: protein kinase C-ε does not play a requisite role in old rabbits. J Appl Physiol 2003; 95: 2563-2569.

69. Dickson EW, Whittaker P, Darling CE, Hirsch DJ, Blehar DJ, Przyklenk K. Brief anoxia induces myocardial ischemic tolerance by an opioid-independent mechanism. Cardiovasc Pathol 2004; 13: 225-229.

70. Colantonio DA, Van Eyk JE, Przyklenk K. Stunned peri-infarct canine myocardium is characterized by degradation of troponin T, not troponin I. Cardiovasc Res 2004: 63; 217-225.

71. Przyklenk K, Whittaker P. In vitro platelet responsiveness to adenosine-mediated ‘preconditioning’ is age-dependent. J Thromb Thrombolysis 2005; 19: 5-10.

72. Przyklenk K, Maynard M, Darling CE, Whittaker P. Infarct size reduction with D-myo-inositol trisphosphate: initial evidence for a functional association between gap junctions and inositol trisphosphate receptors. J Pharmacol Exp Ther 2005; 314: 1386-1392.

73. Darling CE, Jiang R, Maynard M, Whittaker P, Vinten-Johansen J, Przyklenk K. ‘Postconditioning’ via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK 1/2. Am J Physiol 2005; 289: H1618-H1626.

74. Przyklenk K, Maynard M, Whittaker P. Reduction of infarct size with D-myo-inositol trisphosphate: role of PI3-kinase and mitochondrial KATP channels. Am J Physiol 2006; 290: H830-H836.

75. Yuan C, Gou Y, Ravi R, Przyklenk K, Shilkofski N, Diez R, Cole RN, Murphy AM. Myosin binding protein C is differentially phosphorylated upon myocardial stunning in canine and rat hearts: evidence for novel phosphorylation sites. Proteomics 2006: 6: 4176-4186.

76. Przyklenk K, Maynard M, Whittaker P. First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with preconditioning. Am J Physiol 2006: 291: H2008-2012.

77. Linden MD, Whittaker P, Frelinger AL III, Barnard M, Michelson AD, Przyklenk K. Preconditioning ischemia attenuates myocardial indices of platelet activation-aggregation. J Thromb Haemostasis 2006: 4: 2670-2677.

78. Przyklenk K, Whittaker P. Adaptation of a photochemical method to initiate recurrent platelet-mediated thrombosis in small animals. Lasers Med Sci 2006; 22: 42-45.

79. Darling CE, Solari PR, Smith CS, Furman MI, Przyklenk K. ‘Postconditioning’ the human heart: multiple balloon inflations during cardiac catheterization may confer cardioprotection. Basic Res Cardiol 2007; 102: 274-278.

80. Linden MD, Furman MI, Frelinger AL III, Fox ML, Barnard MR, Li Y, Przyklenk K, Michelson AD. Indices of platelet activation as markers of the acuity of coronary artery disease. J Thromb Haemostasis 2007; 5: 761-765.

81. Linden MD, Barnard MR, Frelinger AL, Michelson AD, Przyklenk K. Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models. Thromb Res 2008; 121: 689-698.

82. Przyklenk K, Maynard M, Darling CE, Whittaker P. Aging mouse hearts are refractory to infarct size reduction with postconditioning. J Am Coll Cardiol 2008; 51: 1393-1398.

83. Hüttemann M, Lee I, Pecinova A, Pecina P, Yu H, Przyklenk K, Doan JW. Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in human disease. J Bioenergetics Biomembranes 2008; 40: 445-456.

84. Whittaker P, Przyklenk K. Fibrin architecture in clots: a quantitative polarized light microscopy analysis. Blood Cells Mol Dis: 2009; 42: 51-56.

85. Darling CE, Michelson AD, Volturo GA, Przyklenk K. Platelet reactivity and the identification of acute coronary syndromes in the emergency department. J Thromb Thrombolysis 2009; 28: 31-37.

86. Cohen J, Goedecke E, Cyrkler JE, Mangolds VB, Bateman J, Przyklenk K, Mullen MT. Early glycemic control in critically ill emergency department patients: pilot trial. West J Emerg Med 2010; 11:20-23.

87. Przyklenk K, Frelinger AL III, Linden MD, Whittaker P. Li Y, Barnard MR. Adams J, Morgan M, Al-Shamma H, Michelson AD. Targeted inhibition of the serotonin 5-HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemostasis: 2010; 10: 331-340.

88. Pecina P, Borisenko GG, Belikova NA, Pecinova A, Lee I, Samhan-Arias AK, Przyklenk K, Kagan VE, Hüttemann M. Phosphomimetic substitution of cytochrome c tyrosine 48 decreases respiration and binding to cardiolipin, and abolishes ability to trigger downstream caspase activation. Biochemistry 2010: 49: 6705-14.

89. Dong Y, Undyala VV, Gottlieb RA, Mentzer RM Jr, Przyklenk K. Autophagy: definition, molecular machinery and potential role in myocardial ischemia-reperfusion injury. J Cardiovasc Pharm Ther: 2010; 15: 220-230.

90. Sala Mercado JA, Wider J, Undyala VV, Jahania S, Mentzer RM Jr, Gottlieb RA, Przyklenk K. Profound cardioprotection with chloramphenicol succinate in the swine model of myocardial ischemia-reperfusion injury. Circulation 2010; 122(Suppl I): S179-S184.

91. Przyklenk K, Maynard M, Grenier DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal: 2011; 14: 781-90.

92. Przyklenk, K. Efficacy of cardioprotective ‘conditioning’ strategies in aging and diabetic cohorts: the comorbidity conundrum. Drugs & Aging 2011; 28: 331-43.

93. Ehrman R, Wira C, Lomax A, Hayward A, Marcelin J, Ellis T, Przyklenk K, Volturo G, Mullen M. Etomidate use in severe sepsis and septic shock patients does not contribute to mortality. Intern Emerg Med 2011; 6: 253-57.

94. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, Downey J, Gibbons RJ, Gottlieb RA, Heusch G, Jennings RB, Lefer DJ, Mentzer RM, Murphy E, Ovize M, Ping P, Przyklenk K, Sack MN, Vander Heide RS, Vinten-Johansen J, Yellon DM. New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung and Blood Institute Workshop. Circulation 2011; 134:1172-79.

95. Whittaker P, Przyklenk K. Remote conditioning ischemia provides a potential approach to mitigate contrast media-induced reduction in kidney function: a retrospective case series. Cardiology 2011;119:145-50.

96. Ovize M, Thibault H, Przyklenk K. Myocardial conditioning: opportunities for clinical translation. Circ Res 2013; 113:439-50.

97. Darling CE, Sala Mercado JA, Quiroga-Castro W, Tecco GF, Zelaya FR, Conci EC, Sala JP, Smith CS, Michelson AD, Whittaker P, Welch RD, Przyklenk K. Point-of-care assessment of platelet reactivity in the Emergency Department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study. BMJ Open 2014; 4:e003883.

98. Wider J, Przyklenk K. Ischemic conditioning: the challenge of protecting the diabetic heart. Cardiovasc Diagn Ther 2014; 4:383-96.

99. Heusch G, Botker HE, Przyklenk K, Redington AN, Yellon DM. State-of-the-art review: remote ischemic conditioning. J Am Coll Cardiol 2015; 65:177-95.

100. Przyklenk K. Ischemic ‘conditioning’: pitfalls on the path to clinical translation. Br J Pharmacol 2015; 172:1961-73.

101. Datta NS, Chukkapalli S, Vengalil N, Zhan E, Przyklenk K, Lasley RD. Parathyroid-related peptide protects cardiomyocytes from oxidative stress-induced cell death: first evidence of a novel endocrine-cardiovascular interaction. Biochem Biophys Res Commun 2015: 468:202-7.

102. ** Gremmel T, Yanachkov IB, Yanachkova M, Wright GE, Wider J, Undyala VVR, Michelson AD, Frelinger AL III, Przyklenk K. Synergistic inhibition of both platelet adenosine diphosphate receptors as novel approach to attenuate pathophysiologic platelet aggregation. Arterioscler Thromb Vasc Biol 2016; 36: 501-509.

** selected by ATVB as the best paper on thrombosis published in 2016, with TG awarded the 2017 Karl Link Early Career Investigator Award in Thrombosis

103. Kumar R, Bukowski MJ, Wider JM, Reynolds CA, Calo L, Lepore B, Tousignant R, Jones M, Przyklenk K, Sanderson TH. Mitochondrial dynamics following global cerebral ischemia. Mol Cell Neurosci 2016; 76:68-75.

104. Dong Y, Undyala VVR, Przyklenk K. Inhibition of mitochondrial fission as a molecular target for cardioprotection: critical importance of the timing of treatment. Basic Res Cardiol 2016;111:59.

105. Pearson C, Przyklenk K, Mika V, Ayaz SI, Ellis M, Varade P, Tolomello R, Welch RD. Utility of point of care assessment of platelet reactivity (using the PFA-100®) to aid in diagnosis of stroke. Am J Emergency Med 2017; Epub 15 November 2016.
106. Arnetz BB, Lewalski P, Arnetz J, Breejen K, Przyklenk K. Self-reported and supervisor-observed near-misses by Emergency Medicine residents: Relationship to self-reported stress and unbiased biomarkers of stress. BMJ Open 2017: in review.

 

INVITED REVIEW ARTICLES

1. Przyklenk K, Kloner RA. Free radicals: role in ischemia and infarction. Cardio November 1986: 54-58.

2. Campbell CA, Przyklenk K, Kloner RA. Infarct size reduction: a review of the clinical trials. J Clin Pharmacol 1986, 26: 317-329.

3. Kloner RA, Przyklenk K, Campbell CA. Coronary reperfusion following experimental myocardial infarction. J Cardiac Surg 1987, 2: 291-297.

4. Kloner RA, Przyklenk K. Recent advances in stunned myocardium. Cardiovascular Reviews & Reports 1987; 8: 25-29.

5. Przyklenk K. Oxygen-derived free radicals and stunned myocardium. Free Radical Biol Med 1988; 4: 39-44.

6. Patel B, Kloner RA, Przyklenk K, Braunwald E. Postischemic myocardial stunning: a clinically relevant phenomenon. Ann Int Med 1988; 108: 627-629.

7. Kloner RA, Przyklenk K, Patel B. Altered myocardial states: the stunned and hibernating myocardium. Am J Med 1988; 86 (Suppl A): 14-22.

8. Kloner RA, Przyklenk K. Coronary artery reperfusion for the treatment of acute myocardial infarction. Internal Medicine for the Specialist 1989; 10: 54-65.

9. Przyklenk K, Kloner RA. Stunned myocardium: characteristics and implications. Cardio April 1989: 130-134.

10. Przyklenk K, Kloner RA. What factors predict recovery of contractile function in the canine model of the stunned myocardium? Am J Cardiol 1989; 64: 18F-26F.

11. Przyklenk K, Kloner RA. Relationship between structure and effects of ACE inhibitors: comparative effects in myocardial ischemia/reperfusion injury. British J Clin Pharmacol 1989; 28: 167S-175S.

12. Kloner RA, Przyklenk K. Recent advances in stunned myocardium. [Original 1987 manuscript reprinted as part of the "Classics of the Decade Series", and update 1990]. Cardiovascular Reviews & Reports 1990; 11: 68-74.

13. Mehta PM, Przyklenk K, Kloner RA. Cardioprotective effect of captopril in myocardial ischemia, ischemia/reperfusion and infarction. European Heart J 1990; 11 (Suppl B): 94-99.

14. Kloner RA, Przyklenk K. Progress in cardioprotection: the role of the calcium antagonists. Am J Cardiol 1990; 66: 2H-9H.

15. Kloner RA, Przyklenk K. The stunned and hibernating myocardium. Ann Review Med 1991; 42: 1-8.

16. Kloner RA, Przyklenk K. Adjuvant therapy for coronary reperfusion: role of oxygen radical scavengers? Western J Med 1991; 154: 436-411.

17. Przyklenk K, Kloner RA. Calcium antagonists and the stunned myocardium: importance for clinicians? Cardiovasc Drugs Therapy 1991; 5: 947-952.

18. Przyklenk K, Kloner RA. Calcium antagonists and the stunned myocardium. J Cardiovasc. Pharmacol 1991; 18 (Suppl 10): S93-S101.

19. Ovize M, Li Y, Przyklenk K, Kloner RA. Evidence from experimental models for myocardial protection during ischemia. Current Opinion in Cardiology 1992; 7: 563-570.

20. Przyklenk K, Ovize M, Kloner RA. Transient postischemic contraction: a reliable indicator of viable myocardium? Am J. Cardiac Imaging 1992; 6: 259-266.

21. Kloner RA, Przyklenk K. Dysfunctional myocardium: "dead or alive"? Am J Cardiac Imaging 1992; 6: 197-199.

22. Kloner RA, Przyklenk K. Cardioprotection with angiotensin converting enzyme inhibitors: redefined for the 1990's. Clin Cardiol 1992; 15:95-103.

23. Kloner RA, Przyklenk K. Understanding the jargon: A glossary of terms used (and misused) in the study of ischemia and reperfusion. Cardiovasc Res 1993; 27: 162-166.

24. Przyklenk K, Ovize M, Bauer B, Kloner RA. Ischemic preconditioning: an endogenous cardioprotective phenomenon? Journal of Myocardial Ischemia 1993; 5: 13-24.

25. Przyklenk K, Kloner RA. "Cardioprotection" by ACE inhibitors in acute ischemia and infarction? Basic Res Cardiol 1993; 88 (Suppl I): 139-154.

26. Kloner RA, Przyklenk K, Kay GL. Clinical evidence for stunned myocardium after coronary artery bypass surgery. J Cardiac Surg 1994; 9: 397-402.

27. Kloner RA, Przyklenk K, Shook T, Matthews RV, Burstein S, Cannom DS, Kay GL. Clinical aspects of preconditioning and implications for the cardiac surgeon. J Cardiac Surg 1995: 10: 369-375.

28. Kloner RA, Przyklenk K, Shook T. The role of preconditioning ischemia in the reduction of myocardial infarct size. Editorials in Cardiology 1995; 1: 67-71. [Translated into French: Le rôle du préconditionnement ischémique dans la diminution de la taille de l'infarctus. L'Information Cardiologique 1995; 19: 125-129.]

29. Birnbaum Y, Przyklenk, K, Kloner RA. The time frame of ischemic preconditioning: Is it clinically relevant? J Cardiovasc Pharmacol Ther 1996; 1: 39-346.

30. Schwarz ER, Przyklenk K, vom Dahl J, Schoendube FA, Hanrath P, Kloner RA. Chronic hibernating myocardium: concepts and controversies. Congestive Heart Failure May/June 1997: 12-23.

31. Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E and participants. Medical and cellular implications of stunning, hibernation and preconditioning: an NHLBI workshop. Circulation 1998; 97: 1848-1867.

32. Przyklenk K, Kloner RA. Ischemic preconditioning: exploring the paradox. Prog Cardiovasc Diseases 1998; 40: 517-547.

33. Simkhovich BZ, Przyklenk K, Kloner RA. Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review. Cardiovasc Res 1998; 40: 9-22.

34. Przyklenk K, Simkhovich BZ, Bauer B, Hata K, Zhao L., Elliott GT, Kloner RA. Cellular mechanisms of infarct size reduction with preconditioning: role of calcium? Ann NY Acad Sci 1999; 874: 192-210.

35. Przyklenk K. Key references: Ischemic preconditioning. J Thromb Thrombolysis 2000; 9: 99-103.

36. Kloner RA, Shook T, Cannon CP, Przyklenk K. Ischemic preconditioning: implications for the geriatric heart. Am J Geriatric Cardiol 2001; 10: 145-148.

37. Przyklenk K. Pharmacologic treatment of the stunned myocardium: the concepts and the challenges. Coronary Artery Dis 2001; 12: 363-370.

38. Kloner RA, Speakman MT, Przyklenk K. Ischemic preconditioning: a plea for targeted clinical trials. Cardiovasc Res 2002; 55: 526-533.

39. Przyklenk K, Darling CE, Dickson EW, Whittaker P. Cardioprotection ‘outside the box’: the evolving paradigm of remote preconditioning. Basic Res Cardiol 2003: 98: 149-157.

40. Przyklenk K, Kukreja RC. Sildenafil citrate (Viagra) in experimental models of acute coronary syndromes. Print version: Journal Salud (i) Ciencia 2003. [On-line version: http://www.siicsalud.com/des/des032/03710007i.htm]

41. Linden MD, Frelinger AL III, Barnard MR, Przyklenk K, Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. Seminars Thromb Hemostasis 2004; 5: 501-511.

42. Volturo GA, Mazzola JL, Przyklenk K. The role of antiplatelet therapy in the management of acute coronary syndromes. Expert Opin Drug Safety 2005; 4:541-556.

43. Przyklenk K. Design of novel strategies to limit heart damage in the setting of acute myocardial infarction. Business Briefings: Emergency Medicine Review 2005 (June): 62-64.

44. Darling CE, Przyklenk K. ‘Postconditioning’: A new paradigm for myocardial protection? Current Reviews in Cardiology 2005; 1: 195-201.

45. Linden MD, Frelinger AL III, Przyklenk K, Furman MI, Michelson AD. Aspirin resistance: detection, mechanisms and clinical implications. Current Reviews in Cardiology 2005; 1: 203-211.

46. Przyklenk K, Darling CE, Volutro GA, Michelson AD. On-site assessment of platelet reactivity in the emergency department. Touch Briefings’ Emergency Medicine and Critical Care Review December 2006: 28-30.

47. Young KD on behalf of the 2005-2006 and 2006-2007 Society for Academic Emergency Medicine Grants Committees. Productivity and career paths of previous recipients of Society for Academic Emergency Medicine research grant awards. Acad Emerg Med 2008; 15: 560-566.

48. Vinten-Johansen J, Granfeldt A, Mykytenko J, Undyala VV, Dong Y, Przyklenk K. The multi-dimensional physiological responses to postconditioning. Antioxid Redox Signal 2011: 14; 791-810.

49. Przyklenk K, Whittaker P. Remote ischemic preconditioning: current knowledge, unresolved questions and future priorities. J Cardiovasc Pharm Ther 2011: 16; 255-259.

50. Przyklenk K, Dong Y, Undyala VVR, Whittaker P. Autophagy as a therapeutic target for ischemia-reperfusion injury? Concepts, controversies and challenges. Cardiovasc Res 2012; 94; 197-205.

51. Klionsky DJ et al (total of 1042 authors [alphabetical list], including Przyklenk K). Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 455-544.

52. Sanderson TH, Reynolds CA, Kumar R, Przyklenk K, Hüttemann M. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Molecular Neurobiology 2013;47:9-23.

53. Reynolds CA, Hüttemann M, Przyklenk K, Sanderson TH. Hypoxia-induced damage to the adult and immature brain: molecular mechanism of oxidative damage and the need for targeted therapeutic intervention. Hypoxia: Causes, Types and Management. 2013:346:7-10.

54. Przyklenk K, Whittaker P. Genesis of remote conditioning. Action at a distance: ‘hypotheses non fingo’? J Cardiovasc Med 2013;14:179-85.

55. Przyklenk K. Reduction of myocardial infarct size with ischemic ‘conditioning’: physiologic and technical considerations. Anesthesia & Analgesia 2013; 117:891-901.

56. Calo L, Dong Y, Kumar R, Przyklenk K, Sanderson TH. Mitochondrial dynamics: an emerging paradigm in ischemia-reperfusion injury. Current Pharmaceutical Design 2013;19:6848-57.

57. Simkhovich BZ, Przyklenk K, Kloner RA. Role of protein kinase C in ischemic ‘conditioning’: from first evidence to current perspectives. J Cardiovasc Pharm Ther 2013;18:525-32.

58. Whittaker P, Przyklenk K. From ischemic conditioning to ‘hyperconditioning’: clinical phenomenon and basic science opportunity? Dose Response 2014;12:650-663.

59. Klionsky DJ et al (total of 2035 authors [alphabetical list], including Przyklenk K). Guidelines for the use and interpretation of assays for monitoring autophagy: 3rd Edition. Autophagy 2016;12:1-222.

60. Hausenloy DJ, Barrabes JA, Bøtker HE, Davidson SM, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes H, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda RK, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado M. Ischaemic conditioning and targeting reperfusion: a 30 year voyage of discovery. Basic Res Cardiol 2016;111:70.

61. Datta T, Przyklenk K, Datta NS. Parathyroid hormone-related peptide (PTHrP): a novel endocrine cardioprotective ‘conditioning’ mimetic? J Cardiovasc Pharm Ther 2017: Epub 12 April 2017.

62. Anzell AR, Maizy R, Przyklenk K, Sanderson TH. Mitochondrial quality control and disease: insights into ischemia-reperfusion injury. Molecular Neurobiology 2017: Epub 11 April 2017.

 

EDITORIALS AND INVITED COMMENTARIES

1. Kloner RA, Przyklenk K. Experimental infarct size reduction with calcium channel blockers. J Am Coll Cardiol 1991; 18: 876-878.

2. Kloner RA, Przyklenk K. Hibernation and stunning of the myocardium. N Engl J Med 1991; 325: 1877-1879.

3. Przyklenk K, Kloner RA. Calcium antagonists and the stunned myocardium: A role during ischemia? A role during reperfusion? Cardiovasc Res 1992; 26: 82-84.

4. Kloner RA, Przyklenk K, Whittaker P, Hale SL. Preconditioning-like phenomena and inadvertent preconditioning. J Mol Cell Cardiol 1995; 27: 743-747.

5. Przyklenk K, Kloner RA. Preconditioning: A balanced perspective. British Heart J 1995; 74: 575-577.

6. Przyklenk, K. Oxygen radical scavengers as adjuvant therapy for coronary reperfusion. J Thromb Thrombolysis 1996; 3: 35-40.

7. Przyklenk K, Kloner RA. Role of protein kinase C in ischemic preconditioning: In search of the "pure and simple truth". Basic Res Cardiol 1996; 91: 41-43 and New Paradigms of Coronary Artery Disease: Stunning, Hibernating and Ischemic Preconditioning (G. Heusch and R. Schulz, Eds) Steinkopff, Darmstadt, 1996, p 159-161.

8. Przyklenk K. Lethal myocardial "reperfusion injury": The opinions of good men. J Thromb Thrombolysis 1997; 4: 5-6.

9. Kloner RA, Przyklenk K. Clinical evidence that nisoldipine attenuates stunning in patients post-infarction. Cardiovasc Drugs Therapy 1997; 11: 17-18.

10. Przyklenk K, Hutsell TC, Hata K, Whittaker P. Targeted coronary thrombolysis via “pericardial” administration of lytic agents? J Thromb Thrombolysis 1998; 6: 83-88.

11. Przyklenk K. Cardioprotection with sodium-hydrogen exchange inhibition: an archetype of “bench to bedside”. J Thromb Thrombolysis 1999; 8: 5.

12. Przyklenk K, Heusch G. Late preconditioning against myocardial stunning: does aspirin close the ‘second window’ of endogenous cardioprotection? J Am Coll Cardiol 2003: 41: 1195-1197.

13. Przyklenk K, Whittaker P. Cardioprotection with adenosine: ‘a riddle wrapped in a mystery’. British J Pharmacol 2005; 145; 699-700.

14. Przyklenk K. Reduction of infarct size with ‘postconditioning’: the concept of modified reperfusion. Federaćion Argentina de Cardiologia - 6th Virtual Congress of Cardiology 2009: http://www.fac.org.ar/6cvc/llave/c162/przyklenkk.php

15. Przyklenk K, Undyala VVR, Wider J, Sala-Mercado JA, Gottlieb RA, Mentzer RM Jr. Acute induction of autophagy as a novel strategy for cardioprotection: getting to the heart of the matter. Autophagy 2011; 7: 432-433.

16. Przyklenk K, Whittaker P. Cardioprotection via adaptation to hypoxia: expanding the timeline and targets? Basic Res Cardiol 2011; 106: 325-328.

17. Przyklenk K. Role of adenosine A2B receptor stimulation in ischemic preconditioning: dawn of a new paradigm in cardioprotection. Cardiovasc Res 2012; 96: 195-197.

18. Przyklenk K. ‘Going out on a limb’: SDF-1α/CXCR4 signaling as a mechanism of remote ischemic preconditioning? Basic Res Cardiol 2013; 108; 302.

19. Przyklenk K, Sanderson TH, Hüttemann M. Clinical benefits of remote ischemic preconditioning: new insights . . . and new questions. Circ Res 2014; 114:748-750.

20. Przyklenk K. Role of extracellular vesicles in remote ischemic preconditioning: ‘good things come in small packages’? J Mol Cell Cardiol 2014: 69:83-84.

21. Przyklenk K. microRNA-144: the ‘what’ and ‘how’ of remote ischemic conditioning? Basic Res Cardiol 2014; 109:429.

22. Garratt KN, Whittaker P, Przyklenk K. Remote ischemic conditioning and the long road to clinical translation: lessons learned from ERICCA and RIPHeart. Circ Res 2016; 18:1052-54.


LETTERS TO THE EDITOR

1. Whittaker P, Kloner RA, Przyklenk K. Solicited reply to "Laser-mediated transmural myocardial channels induce a hyalin degeneration of neighboring myocardium" J Am Coll Cardiol 1994; 23: 1518.

2. Kloner RA, Przyklenk K, Cannon CP, Davis VG. Solicited reply to "Is the benefit of preinfarction angina on infarct size due to faster coronary recanalization?" Circulation 1995; 92: 1064-1065.

3. Przyklenk K, Whittaker P. Solicited reply to “A 4-year old rabbit cannot be considered the right model for investigating cardiac senescence” J Am Col. Cardiol 2002; 39: 1701-1702.


BOOK CHAPTERS AND MONOGRAPHS

1. Kloner RA, Przyklenk K, Lange R, Ellis SG. Reperfusion pathophysiology. In: Myocardial Protection in Cardiac Surgery (A.J. Roberts, Ed.) Marcel-Dekker, Inc., New York, 1987, p 29-52.

2. Przyklenk K, Kloner RA. Acute effects of antioxidants in experimental myocardial ischemia and infarction. In: Free Radicals in the Pathophysiology of Heart Disease (P.K. Singal, Ed.) Martinus Nijoff Publishing Co., Boston, 1988, p 227-237.

3. Przyklenk K. Effect of ACE inhibition of acute myocardial ischemia/reperfusion injury. In: Cardioprotection by Converting Enzyme Inhibition: Highlights of Satellite Symposium No. 9 of the 12th International Society of Hypertension (R.M. Zusman, Ed.) Excerpta Medica, Princeton, 1988, p 28-33.

4. Przyklenk K, Whittaker P, Kloner RA. Zofenopril, a newly developed sulfhydryl-containing angiotensin converting enzyme inhibitor, enhances contractile function of stunned myocardium. In: Current Advances in ACE Inhibition (G.A. MacGregor and P.S. Sever, Eds.) Churchill Livingstone, London, 1989, p 279-282.

5. Kloner RA, Przyklenk K, Rahimtoola SH, Braunwald E. Myocardial stunning and hibernation: mechanisms and clinical implications. In: Heart Disease: A Textbook of Cardiovascular Medicine (3rd Edition): Update 11 (E. Braunwald, Ed.) W.B. Saunders Co., New York, 1991, p 241-256.

6. Kloner RA, Przyklenk K. Consequences of ischemia/reperfusion on the coronary microvasculature. In: Myocardial Protection: The Pathophysiology of Reperfusion and Reperfusion Injury (D. Yellon and R.B. Jennings, Ed.) Raven Press, New York, 1992, p 85-103.

7. Kloner RA, Przyklenk, K. Reperfusion injury to the heart: Is it a real phenomenon? In: Cardiovascular Toxicology (2nd Edition) (D. Acosta, Ed.) Raven Press, New York, 1992, p 131-140.

8. Przyklenk K, Kloner RA. Calcium antagonists and the stunned myocardium: importance for clinicians? In: Stunning, Hibernation and Calcium in Myocardial Ischemia and Reperfusion (L. Opie, Ed.) Kluwer Academic Publishers, Boston MA, 1992, p 180-189.

9. Kloner RA, Przyklenk K, Rahimtoola SH, Braunwald E. Myocardial stunning and hibernation: mechanisms and clinical implications. In: Stunning, Hibernation and Calcium in Myocardial Ischemia and Reperfusion (L. Opie, Ed.) Kluwer Academic Publishers, Boston MA, 1992, p 251-280.

10. Kloner RA, Przyklenk K. "First evidence": postischemic dysfunction of viable myocardium and associated abnormalities. In: Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations (R.A. Kloner and K. Przyklenk, Eds.) Marcel-Dekker Inc., New York, 1993, p 17-40.

11. Przyklenk K, Apstein CS. Stunned myocardium in the isolated perfused heart preparation. In: Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations (R.A. Kloner and K. Przyklenk, Eds.) Marcel-Dekker Inc., New York, 1993, 109-130.

12. Przyklenk K, Whittaker P. Other theories: myths, fads or facts? n: Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations (R.A. Kloner and K. Przyklenk, Eds.) Marcel-Dekker Inc., New York, 1993, p 233-248.

13. Przyklenk K, Kloner RA. Calcium antagonists as "treatment" for the stunned myocardium. In: Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations (R.A. Kloner and K. Przyklenk, Eds.) Marcel-Dekker Inc., New York, 1993, p 281-302.

14. Przyklenk K. Angiotensin converting enzyme inhibitors. In: Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations (R.A. Kloner and K. Przyklenk, Eds.) Marcel-Dekker Inc., New York, 1993, p 321-336.

15. Ovize M, Przyklenk K, Kloner RA. Pathophysiology of acute coronary ischemia and reperfusion. In: Current Therapy for Acute Coronary Ischemia (H.L. Lazar, Ed.) Futura Publishing Co., New York, 1993, p 1-32.

16. Przyklenk K, Kloner RA. Diagnosis of stunned and hibernating myocardium. In: Cura Intensiva Cardiologica 1993 (G. Caturelli, Ed.) MGA s.r.l., Rome, 1994, p 36-44.

17. Ovize M, Kloner RA, Przyklenk K. Preconditioning and myocardial contractile function. In: Ischemic Preconditioning: The Concept of Endogenous Cardioprotection (K. Przyklenk, R.A. Kloner, and D. M. Yellon, Eds.) Kluwer Academic Publishers, Norwell MA, 1994, p 41-60.

18. Bauer B, Kloner RA, Przyklenk K. Preconditioning and the coronary vasculature. In: Ischemic Preconditioning: The Concept of Endogenous Cardioprotection (K. Przyklenk, R.A. Kloner, and D. M. Yellon, Eds.) Kluwer Academic Publishers, Norwell MA, 1994, p 61-72.

19. Przyklenk K, Kloner RA, Whittaker P. Synopsis of ischemic preconditioning: What have we learned since 1986? In: Ischemic Preconditioning: The Concept of Endogenous Cardioprotection (K. Przyklenk, R.A. Kloner, and D. M. Yellon, Eds.) Kluwer Academic Publishers, Norwell MA, 1994, 153-170.

20. Kloner RA, Przyklenk K. Is preconditioning relevant to clinical medicine? In: Ischemic Preconditioning: The Concept of Endogenous Cardioprotection (K. Przyklenk, R.A. Kloner, and D. M. Yellon, Eds.) Kluwer Academic Publishers, Norwell MA, 1994, p 173-187.

21. Przyklenk K, Kloner RA. Stunned and hibernating myocardium. In: New Types of Cardiovascular Diseases (J. Willis Hurst, Ed.) Igaku-Shoin Publishers, Inc., New York, 1994, p 24-45.

22. Przyklenk K, Kloner RA. Prevention of lethal myocardial "reperfusion injury": a clinically relevant phenomenon? Monograph: Topics in Preventive Cardiology (4/94) Excerpta Medica, Amsterdam, 1994.

23. Przyklenk K, Whittaker P, Ovize M, and Kloner RA. Reduction of infarct size with preconditioning: "Preconditioning at a distance". In: Myocardial Preconditioning (C.L. Wainwright and J. Parratt, Eds) R.G. Landes Co., Austin TX, 1996, p 79-96.

24. Przyklenk K, Kloner RA, Whittaker P. Increased perfusion via laser-mediated myocardial channels? Importance of appropriate models and endpoints. In: Direct Myocardial Revascularization: History, Methodology, Technology (P. Whittaker and G.S. Abela, Eds) Kluwer Academic Publishers, Norwell MA, 1999, p 61-80.

25. Przyklenk K. Mechanisms of acute cardioprotection with ischemic preconditioning: protein kinase C and beyond. In: Heart Failure: Frontiers in Cardiology (A. Kitabatake, S. Sasayama and G. S. Francis, Eds) Springer-Verlag, Tokyo Japan, 2000, p. 71-79.

26. Darling CE, Przyklenk K. Endogenous cardioprotection: a fresh look. In: Recent Developments in Physiology: Volume 2 (Part II) (SG Pandalai, Ed) Research Signpost, Kerala India, 2004, p. 385-401.

27. Ovize M, Przyklenk K. Mechanical versus ischemic preconditioning. In: Cardiac Mechano-Electric Feedback and Arrhythmias: From Pipette to Patient (P. Kohl, M. Franz and F. Sachs, Eds) Elsevier, Philadelphia PA, 2005, p. 164 – 170.

28. Mentzer, RM Jr., Gottlieb RA, Przyklenk K, Jahania MS. Myocardial protection. In: Cardiac Surgery in the Adult (4th Edition) (L.H. Cohn, Ed) ; McGraw Hill, New York NY, 2012, p. 355 – 379.

 

BOOKS

1. Stunned Myocardium: Properties, Mechanisms and Clinical Manifestations (R.A. Kloner and K. Przyklenk, Eds.)Marcel-Dekker, New York, 1993.

2. Ischemic Preconditioning: The Concept of Endogenous Cardioprotection (K. Przyklenk, R.A. Kloner, and D. M. Yellon, Eds.) Kluwer Academic Publishers, Norwell MA, 1994.


PUBLISHED ABSTRACTS (2005 – present)

1. Jiang R, Darling CE, Maynard M, Whittaker P, Vinten-Johansen J, Przyklenk K. Which ‘survival’ and/or ‘death’ kinases contribute to postconditioning in rabbit heart? J Mol Cell Cardiol 2005; 38: 855.

2. Darling CE, Jiang R, Maynard M, Vinten-Johansen J, Whittaker P, Przyklenk K. Cellular mechanisms of cardioprotection with ‘postconditioning’: role of ERK 1/2 signaling and mitochondrial KATP channels. Acad Emerg Med 2005; 12: 56-57.

3. Przyklenk K, Whittaker P. Age-associated differences in expression of cardioprotective signaling proteins in old versus adult rabbit hearts. Acad Emerg Med 2005; 12: 57.

4. Whittaker P, Rich L, Przyklenk K. Preconditioning with asphyxia enhances recovery after cardiac arrest. Acad Emerg Med 2005; 12: 155.

5. Przyklenk K. Cardioprotection with ischemic preconditioning: is efficacy maintained in aging cohorts? J Heart Dis 2005; 4: 63.

6. Whittaker P, Rich L, Przyklenk K. Short-term survival after cardiac arrest is augmented with preconditioning. Circulation 2005; 112 (Suppl II): II-434.

7. Jiang R, Darling CE, Maynard M, Whittaker P, Vinten-Johansen J, Przyklenk K. Assessment of kinase activities in models of lethal reperfusion injury: critical importance of sampling site. Circulation 2005; 112 (Suppl II): II-1109.

8. Przyklenk K, Maynard M, Whittaker P. First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with ischemic preconditioning. Circ Res 2005; 97: 7. (Late-breaking abstracts published on-line Nov 9, 2005 - DOI: 10.1161/01.RES.0000196463.09130.2b)

9. Linden MD, Frelinger AL III, Furman MI, Krueger LA, Li Y, Fox ML, Hughes A, Lown J, Barnard MR, Przyklenk K, Michelson AD. Detection and mechanisms of GPIIb-IIIa antagonist-induced thrombocytopenia: role for antibody-induced platelet activation. Blood 2005; 106: 1654.

10. Linden MD, Michelson AD, Barnard MR, Frelinger AL III, Furman MI, Przyklenk K. Does adenosine A2 receptor stimulation trigger the favorable ‘anti-platelet’ effect of preconditioning ischemia? Arterioscler. Thromb Vasc Biol 2006: 26:e-46.

11. Linden MD, Michelson AD, Barnard MR, Frelinger AL III, Furman MI, Przyklenk K. In vitro adenosine A2 receptor stimulation inhibits platelet activation in humans. Arterioscler Thromb Vasc Biol 2006: 26:e-58 – e-59.

12. Whittaker P, Przyklenk K. Quantitative assessment of fibrin architecture: novel techniques and staining methods. Arterioscler Thromb Vasc Biol 2006: 26:e-102.

13. Hamblett KM, Cohen JE, Przyklenk K, Darling CE. Emergency department diagnosis of ST-elevation myocardial infarction: confounding effects of gender and diabetes. Acad Emerg Med 2006; 13 (Suppl 1): S37.

14. Darling CE, Czysz AL, Ellberg RA, Ellis JM, Przyklenk K, Volturo G. A triage-based protocol for the rapid diagnosis and treatment of community-acquired pneumonia. Acad Emerg Med 2006; 13 (Suppl 1): S58-S59.

15. Darling CE, Maynard M, Whittaker P, Przyklenk K. ‘Elderly’ mice are refractory to postconditioning-induced cardioprotection. Acad Emerg Med 2006; 3 (Suppl 1): S134.
16. Cohen JE, Goedecke E, Mangolds V, Przyklenk K, Mullen M. First trial of early intensive glycemic control in critically ill emergency department patients. Acad Emerg Med 2006; 13 (Suppl 1): S181.

17. Przyklenk K, Maynard M, Whittaker P. Can ‘elderly’ hearts be rendered resistant to ischemia? D-myo-inositol trisphosphate, but not ischemic preconditioning, limits infarct size in aged mouse hearts. Circ Res 2006; 99: e-25.

18. Darling CE, Pearlman EB, Solari PR, Smith CS, Furman MI, Przyklenk K. ‘Postconditioning’ the human heart: multiple balloon inflations during cardiac catheterization may confer cardioprotection. Circ Res 2006; 99: e-43.

19. Mullen M, Ellis T, Marcelin J, Mangolds V, Przyklenk K. Etomidate use in severe sepsis and septic shock may contribute to relative adrenal insufficiency but not mortality. Acad Emerg Med 2007; 14 (Suppl 1): S187-S188.

20. Whittaker P, Przyklenk K. Novel histological methods to detect and analyze the architecture of early-stage diabetes-induced fibrosis. Diabetes 2007; 56 (Suppl 1): A206.

21. Przyklenk K, Maynard M, Whittaker P. Defects in survival kinase signaling render diabetic myocardium refractory to postconditioning-induced cardioprotection. Diabetes 2007; 56 (Suppl 1): A515.

22. Przyklenk K, Linden MD, Frelinger AL III, Michelson AD. Targeted inhibition of the serotonin 5-HT2A receptor attenuates recurrent platelet-mediated thrombosis in an in vivo model mimicking unstable angina. J Thromb Haemostasis 2007; 5 (Supplement 2): O-W-035.

23. Whittaker P, Przyklenk K. Quantitative assessment of fibrin architecture: novel techniques and staining methods. J Thromb Haemostasis 2007; 5 (Supplement 2): P-S-405.

24. Whittaker P, Donovan JL, Przyklenk K. Long-term warfarin therapy is associated with tissue calcification: influence of treatment duration, age and gender. J Thromb Haemostasis 2007; 5 (Supplement 2): P-M-057 and J Thromb Thrombolysis 2008: 25:125.

25. Przyklenk K. Limiting myocardial ischemia-reperfusion injury: preconditioning, postconditioning and beyond. J Heart Disease 2007; 5: 140.

26. Mullen M, Marcellin J, Ellis T, Lomax A, Przyklenk K. Early antibiotic treatment to severe sepsis/septic shock patients in the emergency department does not improve survival. Ann Emerg Med 2007:50 (Supplement): S98.

27. Przyklenk K, Maynard M, Smith CS, Whittaker P. Postconditioning fails to limit infarct size in the setting of type-2 and type-1 diabetes. Circulation 2007: 116 (Suppl II): II-97.

28. Przyklenk K, Maynard M, Whittaker P. First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with postconditioning. Circulation 2007: 116 (Suppl II): II-21.

29. Przyklenk K, Linden MD, Frelinger AL, Teegarden B, Adams J, Michelson AD. Targeted inhibition of the serotonin 5-HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. Circulation 2007: 116 (Suppl II): II-206.

30. Whittaker P, Donovan JL, Przyklenk K. Reduction in emergency department visits by patients attending an anticoagulation clinic. J Thromb Thrombolysis 2008: 25:132.

31. Darling CE, Volturo GA, Michelson AD, Przyklenk K. Early point of care assessment of platelet reactivity may assist in the rapid identification of acute coronary syndromes in the emergency department. Acad Emerg Med 2008: 15 (Suppl 1): S181.

32. Przyklenk K. Myocardial ischemia-reperfusion injury in the diabetic heart. J Heart Disease 2008; 6: 85.

33. Mullen M, Lomax A, Hayward A, Mangolds V, Przyklenk K. Use of continuous ScVO2 catheters increase ScVO2 monitoring and may improve outcome in early goal-directed therapy. Ann Emerg Med 2008; 52 (Suppl S): S104.

34. Przyklenk K, Maynard M, Greiner DL, Whittaker P. Restoration of normoglycemia re-establishes the infarct-sparing effect of postconditioning in diabetic mice. Circulation 2008; 118 (Suppl II): S-402.

35. Darling CE, Welch R, Yong R, Volturo GA, Michelson AD, Przyklenk K. Point-of-care measurement of platelet reactivity in the emergency department may assist in the early risk assessment of potential acute coronary syndromes. Acad Emerg Med 2009; 16 (Suppl 1): S72.

36. Przyklenk K, Whittaker P. Brief antecedent ‘preconditioning’ ischemia attenuates recurrent platelet-mediated thrombosis: loss of efficacy in aging rats. J Thromb Haemostasis 2009; 7 (Suppl 2): 660.

37. Hüttemann M, Sanderson TH, Whittaker P, Wider J, Lee I, Przyklenk K. Non-pharmacologic modulation of mitochondrial function: a novel strategy to attenuate lethal reperfusion injury in brain and heart. Circulation 2009; 120 (Suppl 2): S641.

38. Sala Mercado JA, Wider J, Jahania S, Mentzer RM Jr, Gottlieb RA, Przyklenk K. Profound cardioprotection with chloramphenicol in the swine model of myocardial ischemia-reperfusion injury. Circulation 2009; 120 (Suppl 2): S795.

39. Mullen M, Hayward A, Lomax A, Przyklenk K. Use of concentrated albumin in the emergency department may improve morbidity in severe sepsis and septic shock. Critical Care Med 2009; 37: A233.

40. Whittaker P, Clemente JL, Garwood CL, Przyklenk K. Power-law analysis: a novel method for evaluation of anticoagulation stability and international normalized ratios. Pathophysiol Haemostasis Thromb 2010; 37 (Suppl 1): A137.

41. Sanderson TH, Undyala VV, Przyklenk K, Kumar R. Molecular mechanisms of cytochrome c release following ischemia-reperfusion: role of Drp1 translocation and increased mitochondrial fission. Circulation 2010; 122 (Suppl): A161.

42. Whittaker P, Przyklenk K. Seasonal differences in anticoagulation stability: novel insights provided by power-law analysis. J Thromb Thrombolysis 2011; 31: 385-6.

43. Whittaker P, Przyklenk K. Myocardial postconditioning initiates a remote protective effect and attenuates contrast-induced kidney dysfunction. Eur Heart J 2011; 32 (Suppl 1): 532.

44. Whittaker P, Chiu HH, Przyklenk K. Increases in red cell distribution width as a biomarker for deep vein thrombosis. Circulation 2011; 124: A16321.

45. Przyklenk K, Whittaker P, Wider J, Undyala VVR, Gottlieb RA, Mentzer RM Jr. Metabolic support of mitochondrial Complex I with yeast Ndi1 evokes significant cardioprotection in the in vivo rat model of acute myocardial infarction. Circulation 2011; 124: A17970.

46. Whittaker P, Przyklenk K. Increased mean platelet volume is associated with venous thromboembolism. Am J Hematol 2012; 87 (S1): S193-S194.

47. Hüttemann M, Lee I, Wider J, Grossman LI, Przyklenk K, Sanderson, T. Non-invasive modulation of cytochrome c oxidase activity with specific infrared light for the treatment of reperfusion injury. Biochimica et Biophysica Acta-Bioenergetics 2012; 1817 (Supplement): S114.

48. Dong Y, Undyala VV, Kumar R, Przyklenk K. Mitochondrial translocation of dynamin-related protein 1 promotes lethal ischemia-reperfusion injury. Circulation 2012; 126: A13470.

49. Przyklenk K, Wright GE, Yanachkov IB. Dual inhibition of platelet ADP P2Y12 and P2Y1 receptors evokes a rapid and robust attenuation of recurrent thrombosis: first in vivo evidence. Circulation 2012; 126: A16092.

50. Reynolds CA, ML Jones, Przyklenk K, Sanderson TH. Translocation of mitochondrial HSP60 precedes cytochrome c release following cerebral hypoxic-ischemic injury in the neonatal rat: a role in apoptosis induction? FASEB J 2013; 27:lb224

51. Dong Y, Undyala VV, Przyklenk K. Inhibition of fission as a novel therapeutic target to attenuate myocardial ischemia-reperfusion injury: critical importance of the timing of treatment. Circulation 2013; 128: A18559.

52. Sanderson TH, Wider J, Reynolds CA, Lepore BD, Przyklenk K, Hüttemann M. Modulation of cytochrome c oxidase activity with specific infrared light wavelengths: noninvasive therapy for reperfusion injury. Circulation 2014, 130:8

53. Dong Y, Undyala VV, Przyklenk K. Inhibition of mitochondrial fission and cardioprotection: does activation of necroptosis play a confounding role? Circulation 2014; 130:A17811.

54. Przyklenk K, Whittaker P. Remote ischemic conditioning, applied during recurrent coronary thrombosis mimicking unstable angina, improves coronary patency. Circulation 2014; 130: 19210.

55. Sanderson TH, Bukowski MJ, Calo L, Przyklenk K, Kumar R. Mitochondrial dynamics during cerebral ischemia/reperfusion injury: the role of Opa1 in cytochrome c release. Stroke 2015; 46 (Suppl 1): AWP234.

56. Pearson C, Mika V, Ayaz SI, Tolomello R, Kulek A, Reed B, Przyklenk K, Welch R. Utility of platelet reactivity to aid in the diagnosis of stroke. Acad Emerg Med 2015; 22 (Supplement 1): S344-5.

57. Wider J, Kulek AR, Undyala VVR, Przyklenk K. Remote ischemic preconditioning: do exosomes play a requisite role in evoking cardioprotection? Circulation 2015; 132:A16479.